GC Cell held a commemorative event at its Yongin Cell Center in Gyeonggi Province last Friday to mark World Cord Blood Day.
The event featured a range of activities designed to raise awareness of the medical value of cord blood and the importance of its storage. Through these programs, GC Cell aimed to encourage a culture of cord blood donation and storage in line with World Cord Blood Day, the company said on Monday.
GC Cell, a cell therapy company, organized programs such as a cord blood bank tour, an introduction to the storage process, case sharing, and a family photo zone, offering various hands-on activities for employees and families.
The significance of organizing such programs ties back to World Cord Blood Day, observed annually on Nov. 15. This commemorative day was established to foster a social atmosphere that supports overcoming diseases through cord blood, caring for and protecting patients.
It originated in the United States in 2017 and was first initiated in Korea by GC Cell at a cord blood bank in 2019.
“Umbilical cord blood, collected from the cord connecting the mother and fetus during delivery, can be used to treat various diseases, including incurable illnesses,” GC Cell CEO Kim Jai-wang said. “GC Cell will continue to make every effort to help families prepare for a healthy future through cord blood storage.”
GC Cell runs a cord blood bank, Lifeline, as its bio-business division. It is a facility certified as excellent by the Ministry of Health and Welfare under the Act on the Management and Research of Cord Blood. Through GC Cell's bio logistics system, it employs a real-name transportation system.
Additionally, dedicated cord blood storage facilities and security systems are installed within GMP-certified facilities, enabling more systematic cord blood storage.
Related articles
- GC Cell introduces multiple myeloma CAR-T therapy from China’s IASO Biotech
- GC Cell and ProEn Therapeutics jointly research solid tumor cell therapy
- GC Cell signs CDMO deal with Dewcell for stem cell-derived artificial platelets
- GC Cell accelerates global expansion of ImmunCell-LC through tech transfer and media export to Indonesia
- GC Cell taps new antibody from Korean biotech to boost CAR-T, CAR-NK programs
- GC Cell's ImmunCell-LC shows 68% reduction in HCC recurrence risk
- GC Cell aims to go global with Immuncell-LC backed by long-term data
- GC Cell to present long-term efficacy of Immuncell-LC at ASCO GI 2025
